In India, where urban sleep debt is rising, obesity rates are increasing, and CPAP adoption remains minimal, a pill could theoretically transform access. A decades-old therapeutic stalemate in sleep medicine is poised to break. For the first time, a pharmaceutical treatment for obstructive sleep apnea (OSA) is approaching the U.S. market. Apnimed, a Boston-based clinical-stage…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
